Pharmaxis to raise further funds

By Renate Krelle
Tuesday, 02 November, 2004

Following its recent announcement of a successful Phase III trial of the successful completion of a Phase III clinical trial for its asthma diagnostic and treatment management tool Aridol, Sydney's Pharmaxis (ASX:PXS) has entered a trading halt -- to be lifted tomorrow morning -- pending the announcement of details of a placement and share purchase plan.

The company will conduct the placement via a bookbuild.

Sleep apnoea patients who use CPAP live longer: study

CPAP therapy has been found to significantly reduce the risk of death for people with obstructive...

Does exercise really extend lifespan? It's complicated

Physical activity is seen as a way to extend the human lifespan, but the benefits of physical...

Nature helps to relieve physical pain

Experiencing nature, even in the form of watching nature videos, can alleviate acute physical pain.

Content from other channels on our network

GLP-1 weight loss drugs' effect on food and drink choices

Heat and Control announces acquisition of Tek-Dry Systems and Hunt Heat Exchangers

Meat industry handling and freezing solutions on show at IFFA

Making the mark for egg producers

$25K FaBA grant to advance antibiotic detection in food

Rising cyber threats to Australia's industrial sector demand urgent action

Cyber attacks on water and electricity operators on the rise: study

Greensteel Australia to build next‍-‍generation steel mill

Omron and Cognizant partner on IT‍–‍OT integration

Encoders in motion control applications: Noise and signal distortion considerations

APHA calls "bulldust" on claims insurers cannot pay in full

Healthscope proposes Northern Beaches Hospital 'hand-back'

IVF incident: "All of us at Monash IVF are devastated"

All metropolitan public hospitals miss out on green light

Psychologist training pathway review launched